Trial · NCT07914634
Virtual Reality Assisted Trauma Focused CBT
NCT07914634, Not applicable, Recruiting, Queen's University, Belfast
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Virtual Reality Assisted Trauma Focused CBT. Trials, record NCT07914634. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07914634
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Virtual Reality Assisted Trauma Focused CBT
- NCT number
- NCT07914634
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Queen's University, Belfast
- Conditions
- PTSD - Post Traumatic Stress Disorder
- Interventions
- VR Photoscan, Trauma-Focused Cognitive Behavioural Therapy (TF-CBT)
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PCL-5 | Baseline (week 1) and weekly throughout treatment (up to 20 weeks max) | The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses the severity of PTSD symptoms. The measure covers four symptom clusters: intrusion, avoidance, negative alterations in cognitions and mood, and alterations in arousal and reactivity. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity and therefore worse outcomes. The PCL-5 will be administered at baseline and weekly throughout treatment to monitor changes in PTSD symptoms. |
| Secondary | BDI-II | Baseline (week 1) and end of treatment (up to 20 weeks max) | The Beck Depression Inventory-II (BDI-II) is a 21-item self-report measure used to assess the severity of depressive symptoms. Each item corresponds to a symptom of depression and is scored on a 4-point scale ranging from 0 to 3. Total scores range from 0 to 63, with higher scores indicating greater depressive symptom severity and therefore worse outcomes. The BDI-II will be administered at baseline and at the end of treatment to assess changes in depressive symptoms. |
| Secondary | ITQ | Baseline (week 1), then weekly up to week 20 (if therapy was not completed before) | The International Trauma Questionnaire (ITQ) is an 18-item self-report measure designed to assess symptoms of PTSD and Complex PTSD in accordance with ICD-11 diagnostic criteria. The questionnaire assesses PTSD symptoms, disturbances in self-organisation (DSO), and associated functional impairment. Items are rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The six PTSD symptom items and six DSO symptom items each produce scores ranging from 0 to 24. The combined PTSD and DSO symptom score ranges from 0 to 48, with higher scores indicating greater trauma-related symptom severity and therefore worse outcomes. The ITQ will be administered at baseline and at the end of treatment to assess changes in trauma-related symptoms. |
| Secondary | CORE-OM | Baseline (week 1) and end of treatment (up to 20 weeks max) | The Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM) is a 34-item self-report measure designed to assess psychological distress and changes associated with psychological therapy. The questionnaire covers four domains: subjective wellbeing, problems and symptoms, life functioning, and risk. Each item is rated on a 5-point scale ranging from 0 (not at all) to 4 (most or all of the time). The mean item score ranges from 0 to 4 and can be multiplied by 10 to produce a clinical score ranging from 0 to 40. Higher scores indicate greater psychological distress and therefore worse outcomes. The CORE-OM will be administered at baseline and at the end of treatment to assess changes in psychological wellbeing. |
| Secondary | CORE-10 | Weekly throughout treatment (up to 20 weeks max) | The Clinical Outcomes in Routine Evaluation - 10 (CORE-10) is a 10-item self-report measure used to monitor psychological distress and changes in mental health during treatment. The questionnaire assesses symptoms, functioning and risk, and is designed for routine session-by-session monitoring. Each item is rated on a 5-point scale ranging from 0 (not at all) to 4 (most or all of the time). Total scores range from 0 to 40, with higher scores indicating greater psychological distress and therefore worse outcomes. The CORE-10 will be administered weekly throughout treatment to monitor changes in psychological wellbeing. |
| Secondary | IPQ | Following the first use of VR Photoscan during treatment (approx week 5) | The Igroup Presence Questionnaire (IPQ) is a 14-item self-report measure designed to assess the subjective experience of presence within a virtual environment. The questionnaire measures spatial presence, involvement and experienced realism, alongside a general presence item. Items are rated on a 7-point scale, which can be scored from -3 to +3. Mean scores for each domain range from -3 to +3, with higher scores indicating a stronger sense of presence, involvement or perceived realism within the virtual environment. The IPQ will be administered following the first session in which VR Photoscan technology is used to assess the participant's experience of the virtual environment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07914634
GET https://conductscience.org/api/trials/v1/NCT07914634/registered